CardioFocus
Marlborough, US · Delaware corporation · 2 known investors
Find your way into CardioFocus
8 people in our graph share verified history with the CardioFocus team — schools, employers, funds. One of them is your warm intro.
Lisa Granickunlockedknows Anjie Roldan · together at CardioFocus (overlapped)
×3knows the team · via Danforth Advisors
×4knows the team · via CardioFocus
CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control. The company's portfolio includes the Centauri™ System and next-generation platforms designed for diverse ablation strategies in electrophysiology practices worldwide.
Founders & leadership
LJ
Lauren JenningsExecutive
WC
Warren ClarkExecutive
SS
Stephen SagoninPresident and CEO
AR
Anjie RoldaninVP Finance and Administration2001–2016Anjie Roldan is Executive Officer at CardioFocus, which develops Pulsed Field Ablation technologies for treating cardiac arrhythmias. She previously worked as a finance consultant advising startups on financial strategy, accounting operations, and investor relations.
WR
Warren R. Clark IIIExecutive
SS
Stephan S. OgilvieinCEO
Board
BR
Bruce RobertsonBoard director
CK
Christopher KroegerBoard director
OA
Omar AmiranaBoard director
JG
James GarveyBoard director
PL
CL
Charles LarsonBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$128.7M disclosed across 10 rounds · 2014–2023
▶$27.2MraisedFeb 2023 · 4 investors · Other TechnologyRule 506(b)
▶$27.2MraisedFeb 2023 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- David KhoDirector
- Charles LarsenDirector
- Stephan OgilvieExecutive Officer
- Bruce RobertsonDirector
- Scott FletcherExecutive Officer
- Gwen WatanabeDirector
- Offering amount
- $31.8M
- Amount sold
- $27.2M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedApr 2022 · 12 investors · Other TechnologyRule 506(b)
▶$4MraisedApr 2022 · 12 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Stephan OgilvieExecutive Officer
- Paul LaVioletteDirector
- Charles LarsenDirector
- Bruce RobertsonDirector
- Patrick WethingtonDirector
- Omar AmiranaDirector
- Burke BarrettExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $4M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedJul 2020 · 13 investors · Other TechnologyRule 506(b)
▶$12MraisedJul 2020 · 13 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Paul LaVioletteDirector
- Burke BarrettExecutive Officer, Director
- Omar AmiranaDirector
- Bruce RobertsonDirector
- Charles LarsenDirector
- Patrick WethingtonDirector
- Offering amount
- $15M
- Amount sold
- $12M
- Minimum investment
- $10K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMay 2019 · 17 investors · BiotechnologyRule 506(b)
▶$8MraisedMay 2019 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- OMAR AMIRANADirector
- PAUL LAVIOLETTEDirector
- OMARI BOUKNIGHTExecutive Officer
- CHRISTOPHER A. KROEGERDirector
- GREG MADDENDirector
- BRUCE C. ROBERTSONDirector
- BURKE BARRETTExecutive Officer
- PATRICK WETHINGTONDirector
- CHARLES E. LARSENDirector
- Offering amount
- $12M
- Amount sold
- $8M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13MraisedApr 2018 · 1 investors · BiotechnologyRule 506(b)
▶$13MraisedApr 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PATRICK WETHINGTONDirector
- WARREN R. CLARK, IIIExecutive Officer
- BURKE BARRETTExecutive Officer
- OMAR AMIRANADirector
- PAUL LAVIOLETTEExecutive Officer, Director
- GREG MADDENDirector
- BRUCE C. ROBERTSONDirector
- CHARLES E. LARSENDirector
- CHRISTOPHER A. KROEGERDirector
- Offering amount
- $21M
- Amount sold
- $13M
- Sales commissions
- $260K
- Placement agents
- TRUMP SECURITIES LLC
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedMar 2017 · 26 investors · BiotechnologyRule 506(b)
▶$20.2MraisedMar 2017 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PAUL LAVIOLETTEExecutive Officer, Director
- WARREN CLARK, IIIExecutive Officer
- BRUCE C. ROBERTSONDirector
- CHRISTOPHER KROEGERDirector
- CHARLES LARSENDirector
- JAMES GARVEYDirector
- OMAR AMIRANADirector
- BURKE BARRETTExecutive Officer
- PATRICK J. WETHINGTONDirector
- Offering amount
- $32.1M
- Amount sold
- $20.2M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMay 2016 · BiotechnologyRule 506(b)
▶$8MraisedMay 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- OMAR ANIRANADirector
- CHRISTOPHER A. KROEGERDirector
- CHARLES E. LARSENDirector
- WARREN R. CLARK, IIIExecutive Officer
- JAMES GARVEYDirector
- PAUL LAVIOLETTEDirector
- BRUCE C. ROBERTSONDirector
- Offering amount
- $12M
- Amount sold
- $8M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$31.7MraisedJan 2015 · 32 investors · Other TechnologyRule 506(b)
▶$31.7MraisedJan 2015 · 32 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce RobertsonDirector
- Lauren JenningsExecutive Officer
- Christopher KroegerDirector
- Omar AmiranaDirector
- Warren ClarkExecutive Officer
- James GarveyDirector
- Paul LaVioletteExecutive Officer, Director
- Stephen SagonExecutive Officer, Director
- Charles LarsenDirector
- Anjie RoldanExecutive Officer
- Offering amount
- $33.2M
- Amount sold
- $31.7M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Boston Scientific16 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Rf Surgical12 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Topera9 shared keywordsAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Oup7 shared keywordsOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Companies competing with CardioFocus for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CardioFocus do?
- CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control. The company's portfolio includes the Centauri™ System and next-generation platforms designed for diverse ablation strategies in electrophysiology practices worldwide.
- Who are CardioFocus's investors?
- CardioFocus's investors include BioBrit, SV Health Investors.
- How much funding has CardioFocus raised?
- CardioFocus has disclosed $128.7M raised across 10 rounds.
- Where is CardioFocus headquartered?
- CardioFocus is headquartered in Marlborough, US.